ALNY · Alnylam Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ALNY

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.71B	$2.25B	$844.29M	$1.04B	$492.85M	$492.85M
Cost of Revenue	$677.17M	$306.51M	$268.22M	$140.17M	$115.00M	$78.05M
Gross Profit	$3.04B	$1.94B	$576.07M	$897.24M	$377.85M	$414.80M
R&D	$1.32B	$1.13B	$1.00B	$883.01M	$792.16M	$654.82M
SG&A	$1.21B	$975.53M	$795.65M	$770.66M	$620.64M	$588.42M
Total Operating Expenses	$3.21B	$2.43B	$2.11B	$1.82B	$1.55B	$1.32B
D&A	$54.80M	$55.10M	$51.60M	$39.10M	$36.80M	$30.20M
Operating Income	$501.58M	($176.88M)	($282.18M)	($785.07M)	($708.65M)	($828.44M)
Interest Expense	$252.63M	$141.86M	$121.22M	$155.97M	$143.02M	$84.50M
Income Tax	$9.40M	($99.22M)	$6.72M	$4.16M	$680.0K	$2.68M
Net Income	$313.75M	($278.16M)	($440.24M)	($1.13B)	($852.82M)	($858.28M)
EPS - Basic	$2.39	($2.18)	($3.52)	($9.30)	($7.46)	-
EPS - Diluted	$2.33	($2.18)	($3.52)	($9.30)	($7.46)	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$1.66B	$966.43M	$812.69M	$866.39M	$819.98M	$496.58M
Accounts Receivable	$777.57M	$405.31M	$327.79M	$237.96M	$198.57M	$102.41M
Inventory	$82.72M	$78.51M	$89.15M	$128.96M	$86.36M	$75.20M
Accounts Payable	$115.72M	$88.42M	$55.52M	$98.09M	$73.43M	$51.97M
Current Assets	$4.05B	$3.30B	$2.98B	$2.69B	$2.81B	$2.61B
Total Assets	$4.97B	$4.24B	$3.83B	$3.55B	$3.64B	$3.41B
Current Liabilities	$1.47B	$1.19B	$967.79M	$767.91M	$695.71M	$585.27M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$4.18B	$4.17B	$4.05B	$3.70B	$3.06B	$2.39B
Stockholders' Equity	$789.18M	$67.09M	($220.64M)	($158.22M)	$588.20M	$1.02B
Retained Earnings	($6.70B)	($7.29B)	($7.01B)	($6.57B)	($5.44B)	($4.59B)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$524.08M	($8.31M)	$104.16M	($541.27M)	($641.69M)	($614.96M)
Investing Cash Flow	$436.33M	($116.84M)	($336.35M)	$169.35M	($273.30M)	($435.52M)
Financing Cash Flow	($305.19M)	$294.16M	$172.13M	$425.75M	$1.25B	$994.98M
CapEx	$58.70M	$34.28M	$62.21M	$72.06M	$76.37M	$70.36M
Free Cash Flow	$465.38M	($42.59M)	$41.95M	($613.33M)	($718.07M)	($685.32M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	81.8%	86.4%	68.2%	86.5%	76.7%	84.2%
Operating margin	13.5%	-7.9%	-33.4%	-75.7%	-143.8%	-168.1%
EBITDA margin	15.0%	-5.4%	-27.3%	-71.9%	-136.3%	-162.0%
Net margin	8.4%	-12.4%	-52.1%	-109.0%	-173.0%	-174.1%
Free cash flow margin	12.5%	-1.9%	5.0%	-59.1%	-145.7%	-139.1%
FCF / Net income	1.48	0.15	-0.10	0.54	0.84	0.80
R&D / Revenue	35.5%	50.1%	119.0%	85.1%	160.7%	132.9%
SG&A / Revenue	32.6%	43.4%	94.2%	74.3%	125.9%	119.4%
Effective tax rate	2.9%	-	-	-	-	-
Return on assets	6.3%	-6.6%	-11.5%	-31.9%	-23.4%	-25.2%
Return on equity	39.8%	-414.6%	199.5%	714.9%	-145.0%	-84.5%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	2.76	2.78	3.08	3.51	4.04	4.47
Quick ratio	2.71	2.71	2.99	3.34	3.91	4.34
Cash ratio	1.13	0.81	0.84	1.13	1.18	0.85
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	2.0x	-1.2x	-2.3x	-5.0x	-5.0x	-9.8x
Equity multiplier	6.29	63.20	-17.36	-22.41	6.19	3.35
Liabilities / Assets	0.84	0.98	1.06	1.04	0.84	0.70
Efficiency
Asset turnover	0.75	0.53	0.22	0.29	0.14	0.14
Inventory turnover	8.19	3.90	3.01	1.09	1.33	1.04
Days sales outstanding	76d	66d	142d	84d	147d	76d
Days inventory outstanding	45d	93d	121d	336d	274d	352d
Days payable outstanding	62d	105d	76d	255d	233d	243d
Cash conversion cycle	59d	54d	187d	164d	188d	185d
Valuation
P / E	170.7x	-	-	-	-	-
P / B	67.9x	447.7x	-	-	33.2x	-
P / S	14.4x	13.4x	28.3x	27.9x	39.6x	-
EV / EBITDA	93.3x	-	-	-	-	-
Growth
Revenue growth (YoY)	65.2%	166.3%	-18.6%	110.5%	0.0%	124.3%
Revenue CAGR (3y)	53.0%	65.8%	19.7%	67.8%	118.6%	-
Revenue CAGR (5y)	49.8%	59.2%	78.1%	-	-	-
Gross profit growth (YoY)	56.4%	237.1%	-35.8%	137.5%	-8.9%	88.8%
Operating income growth (YoY)	-	37.3%	64.1%	-10.8%	14.5%	11.8%
Net income growth (YoY)	-	36.8%	61.1%	-32.6%	0.6%	3.1%
EPS growth (YoY)	-	38.1%	62.2%	-24.7%	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	-	-	-	14.6%	-4.8%	-63.7%
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	1076.3%	-	-39.5%	-	-42.1%	-29.4%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$9.58B total

Product$2.99B · 31.2%

TTR$2.49B · 26.0%

Amvuttra$1.73B · 18.1%

Collaborations$553.37M · 5.8%

Rare$499.92M · 5.2%

License Obligation$300.00M · 3.1%

License$300.00M · 3.1%

GIVLAARI$205.72M · 2.1%

Royalty$174.02M · 1.8%

Development Services Obligation$89.00M · 0.9%

OXLUMO$68.47M · 0.7%

ONPATTRO$62.13M · 0.6%

Other License Programs$50.37M · 0.5%

Research Services Obligation$39.52M · 0.4%

C5 License Obligation$21.64M · 0.2%

Product And Service Other$5.88M · 0.1%

Regeneron Technology Transfer Obligation$2.43M · 0.0%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

0.37

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✗No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing ALNYLAM PHARMACEUTICALS against the 5 most active filers in the same SIC group.